SEARCH:   Advanced

Blood, 15 October 2008, Vol. 112, No. 8, pp. 3500-3507. Prepublished online as a Blood First Edition Paper on July 29, 2008; DOI 10.1182/blood-2008-02-141689. This Article Full Text Full Text (PDF) Supplemental Tables All Versions of this Article: blood-2008-02-141689v1 112/8/3500    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Lee, S. J. Articles by Maziarz, R. T. Search for Related Content PubMed PubMed Citation Articles by Lee, S. J. Articles by Maziarz, R. T. Related Collections Transplantation Clinical Trials and Observations Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  TRANSPLANTATION Impact of prior imatinib mesylate on the outcome of hematopoietic cell transplantation for chronic myeloid leukemia Stephanie J. Lee1, Manisha Kukreja2, Tao Wang2, Sergio A. Giralt3, Jeffrey Szer4, Mukta Arora5, Ann E. Woolfrey1, Francisco Cervantes6, Richard E. Champlin3, Robert Peter Gale7, Joerg Halter8, Armand Keating9, David I. Marks10, Philip L. McCarthy11, Eduardo Olavarria12, Edward A. Stadtmauer13, Manuel Abecasis14, Vikas Gupta9, H. Jean Khoury15, Biju George16, Gregory A. Hale17, Jane L. Liesveld18, David A. Rizzieri19, Joseph H. Antin20, Brian J. Bolwell21, Matthew H. Carabasi22, Edward Copelan21, Osman Ilhan23, Mark R. Litzow24, Harold C. Schouten25, Axel R. Zander26, Mary M. Horowitz2, and Richard T. Maziarz27 1 Fred Hutchinson Cancer Research Center, Seattle, WA; 2 Center for International Blood and Marrow Transplant Research, Medical College of Wisconsin, Milwaukee; 3 M. D. Anderson Cancer Center, Houston, TX; 4 Royal Melbourne Hospital, Parkville, Australia; 5 University of Minnesota Medical Center, Minneapolis; 6 Hospital Clinic, Barcelona, Spain; 7 Center for Advanced Studies in Leukemia, Los Angeles, CA; 8 University Hospital Basel, Basel, Switzerland; 9 Princess Margaret Hospital for Children, Toronto, ON; 10 Bristol Children's Hospital, Bristol, United Kingdom; 11 Roswell Park Cancer Institute, Buffalo, NY; 12 Hammersmith Hospital, London, United Kingdom; 13 Hospital of the University of Pennsylvania, Philadelphia; 14 Instituto Portugues de Oncologia, Lisboa, Portugal; 15 Emory University School of Medicine, Atlanta, GA; 16 Christian Medical College Hospital, Tamil Nadu, India; 17 St Jude Children's Research Hospital, Memphis, TN; 18 University of Rochester Medical Center, NY; 19 Duke University Medical Center, Durham, NC; 20 Dana-Farber Cancer Institute, Boston, MA; 21 Cleveland Clinic Foundation, OH; 22 Thomas Jefferson University Hospital, Philadelphia, PA; 23 Ibni Sinai Hospital, Ankara, Turkey; 24 Mayo Clinic, Rochester, MN; 25 University Hospital Maastricht, Maastricht, The Netherlands; 26 University Hospital Eppendorf, Hamburg, Germany; and 27 Oregon Health & Science University, Portland Imatinib mesylate (IM, Gleevec) has largely supplanted allogeneic hematopoietic cell transplantation (HCT) as first line therapy for chronic myeloid leukemia (CML). Nevertheless, many people with CML eventually undergo HCT, raising the question of whether prior IM therapy impacts HCT success. Data from the Center for International Blood and Marrow Transplant Research on 409 subjects treated with IM before HCT (IM+) and 900 subjects who did not receive IM before HCT (IM–) were analyzed. Among patients in first chronic phase, IM therapy before HCT was associated with better survival but no statistically significant differences in treatment-related mortality, relapse, and leukemia-free survival. Better HLA-matched donors, use of bone marrow, and transplantation within one year of diagnosis were also associated with better survival. A matched-pairs analysis was performed and confirmed a higher survival rate among first chronic phase patients receiving IM. Among patients transplanted with advanced CML, use of IM before HCT was not associated with treatment-related mortality, relapse, leukemia-free survival, or survival. Acute graft-versus-host disease rates were similar between IM+ and IM– groups regardless of leukemia phase. These results should be reassuring to patients receiving IM before HCT. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: M. Baccarani, J. Cortes, F. Pane, D. Niederwieser, G. Saglio, J. Apperley, F. Cervantes, M. Deininger, A. Gratwohl, F. Guilhot, et al. Chronic Myeloid Leukemia: An Update of Concepts and Management Recommendations of European LeukemiaNet J. Clin. Oncol., December 10, 2009; 27(35): 6041 - 6051. [Abstract] [Full Text] [PDF] E. Jabbour, J. E. Cortes, and H. M. Kantarjian Suboptimal Response to or Failure of Imatinib Treatment for Chronic Myeloid Leukemia: What Is the Optimal Strategy? Mayo Clin. Proc., February 1, 2009; 84(2): 161 - 169. [Abstract] [Full Text] [PDF]

	Copyright © 2008 by American Society of Hematology         Online ISSN: 1528-0020